Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-finding trial of naronapride in idiopathic or diabetic gastroparesis
2021-002254-86Phase 2Active
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naronapride in idiopathic gastroparesis (IG) and diabetic gastroparesis (4 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Change in average weekly total symptom score. Started May 2022; status: active.
02
Drugs
naronapride
03
Conditions
idiopathic gastroparesis (IG)diabetic gastroparesis
Beyond the preview
Go deeper on 2021-002254-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002254-86.